Rezzayo
What Rezzayo is used for
Rezzayo is indicated for the treatment of invasive candidiasis in adults. Consideration should be given to official guidance on the appropriate use of antifungal agents.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Rezzayo
- Active substance
- rezafungin
- Disease area
- Candidiasis; Candidiasis, Invasive
- Medicine group
- Antimycotics for systemic use
- ATC code
- J02AX08
- Marketing authorisation holder
- Mundipharma GmbH
- Authorised in the EU since
- 2023
Official information
In the USA
Same active substance: Rezzayo
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Rezzayo used for?
Rezzayo is indicated for the treatment of invasive candidiasis in adults. Consideration should be given to official guidance on the appropriate use of antifungal agents.
What is the active substance in Rezzayo?
Rezzayo contains rezafungin.
Who makes Rezzayo?
The EU marketing authorisation holder is Mundipharma GmbH.
Is Rezzayo an orphan medicine?
Yes. Rezzayo is designated an orphan medicine in the EU, for a rare disease (Candidiasis; Candidiasis, Invasive).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU